Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might […]
Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »
Have you had the chance to play around on ChatGPT, the open AI? It can “talk” to you in text kind of like a person. I have tried it out. It’s quite interesting to type in scientific questions and see what pops out. Often it is high-quality text and solid ideas, but not always. You
Weekly reads: ChatGPT as author, COVID pub concern, CRISPR kit Read More »
If you’ve never heard of the KRAS G12C mutation, it’s a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here’s a
Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs Read More »
Dr. Paolo Macchiarini exemplifies how things can change quickly in the stem cell world and go from sky highs to deep lows. Stem cell rollercoasters Over the years, a few academic stem cell researchers as well as some operators in the unproven clinic sphere have had dizzying ups and downs. There’s John Kosolcharoen. His company
Paolo Macchiarini guilty in criminal stem cell case but does a Houdini again Read More »
This has been one of those weeks where I spent some time thinking about taking risks in science. How much risk one should take? Risks can come in many forms. It could be at the core level at the bench doing specific experiments and not others. There’s risk in clinical trials, and even in advocacy. Sometimes
Weekly science reads: Macchiarini trial, somites, CRISPR babies Read More »
I’m fascinated by the idea of making food from cells grown in a lab and especially the newest idea of lab-grown chocolate. While lab-grown meat has gotten the most attention, (see my recent post on test-tube meat: Not Old MacDonald’s Farm: is the future lab-grown meat?) I’d say that the coolest application of making food from
Biotech California Cultured aims to sell lab-grown chocolate Read More »
The fact that a person for the first time has received a heart transplant from a pig and it was a genetically modified pig made big news this week. Organ transplant waiting lists are a huge problem so if this kind of approach can be proven to be safe and effective, it would be a
Recommended reads: pig heart transplant, lasers, $11K pub fee Read More »
I’ve been concerned that the journal Stem Cells Translational Medicine has been publishing some iffy papers from unproven stem cell clinics recently including from a Panama stem cell clinic called the Stem Cell Institute. Back in 2019, I took the unusual step of raising the question of whether a Stem Cells Translational Medicine paper from Neil Riordan,
Questions remain after Stem Cells Translational Medicine retracts clinic pub Read More »
The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads. However, first I wanted to give
The Niche weekend reads: Editas mess, The Niche updates, papers Read More »
I’m taking a short break today from working on a big grant to put out this weekly reads post including on Sox transcription factors, cord blood paper controversy, and other interesting papers such as one on CTCF and chromatin domains after mitosis that really struck me. I can actually see blue sky today here in
Weekly reads: CTCF, Sox transcription factors, Clinic fires back, more Read More »